English

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder | World Peptide Foundation

Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:44 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

ClinicalTrials.gov · NCT02883595 · Registry updated: 2019-04-04

Condition / research focus: Sepsis
Sponsor: Sun Yat-sen University
Countries with listed sites: China
Registry dates and results: Start: 2016-03-31. Completion: 2016-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

thymosin alpha 1 (drug) — also listed as: thymalfasin
Placebo (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Phase 4CompletedINTERVENTIONAL

Optimized Treatment and Regression of HBV-induced Early Cirrhosis

ClinicalTrials.gov · NCT01938820 · Registry updated: 2018-07-27

Condition / research focus: Liver Cirrhosis
Sponsor: Beijing Friendship Hospital
Countries with listed sites: China
Registry dates and results: Start: 2013-06. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

entecavir (drug) — also listed as: entecavir dispersible tablets
Thymosin-α (drug) — also listed as: Zadaxin

Where the study takes place — 21 listed sites

Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
302 Military Hospital Of China
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College, Huazhong University of Science ＆Technology
Wuhan, Hubei, China
Site recruitment: Not reported
The Affiliated Hospital of Yanbian University
Yanji, Jilin, China
Site recruitment: Not reported
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Huashan Hospital, FuDan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Site recruitment: Not reported
The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

ClinicalTrials.gov · NCT01943617 · Registry updated: 2018-07-27

Condition / research focus: Liver Cirrhosis
Sponsor: Beijing Friendship Hospital
Countries with listed sites: China
Registry dates and results: Start: 2013-06. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Entecavir (drug) — also listed as: Entecavir dispersible tablets
Thymosin-α (drug) — also listed as: Zadaxin

Where the study takes place — 21 listed sites

Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
302 Military Hospital Of China
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
PeKing University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
NanfangHospital,Southern Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College ,Huazhong University of Science ＆Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University
Hangzhou, Jiangsu, China
Site recruitment: Not reported
The Affiliated Hospital of Yanbian University
Yanbian, Jilin, China
Site recruitment: Not reported
RenjiHospital,Shanghai Jiao Tong University,School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Huashan Hospital FuDan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Site recruitment: Not reported
The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B

ClinicalTrials.gov · NCT02366208 · Registry updated: 2015-02-19

Condition / research focus: Hepatitis B, Chronic
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2011-05. Completion: 2013-08 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEG-Tα1 (drug) — also listed as: Polyethylene Glycol Thymosin alpha1
Placebo to match PEG-Tα1 (drug)
Adefovir (drug)

Where the study takes place — 12 listed sites

302 Military Hoapital of China
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Hainan General Hospital
Haikou, Hainan, China
Site recruitment: Not reported
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Site recruitment: Not reported
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Not reported
81 Military Hospital of China
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Site recruitment: Not reported
The First Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B

ClinicalTrials.gov · NCT02366247 · Registry updated: 2015-02-19

Condition / research focus: Hepatitis B, Chronic
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2013-08. Completion: 2016-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PEG-Tα1 (drug) — also listed as: Polyethylene Glycol thymosin alpha1
Placebo to match PEG-Tα1 (drug)
Adefovir (drug)

Where the study takes place — 32 listed sites

302 Military Hoapital of China
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Southwest Hospital
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Site recruitment: Not reported
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Hainan General Hospital
Haikou, Hainan, China
Site recruitment: Not reported
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Site recruitment: Not reported
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Site recruitment: Not reported
People's Hospital of Wuhan University
Wuhan, Hubei, China
Site recruitment: Not reported
Zhongshan Hospital of Hubei Province
Wuhan, Hubei, China
Site recruitment: Not reported
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Not reported
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Not reported
The First Affiliated Hospital of South China University
Hengyang, Hunan, China
Site recruitment: Not reported
81 Military Hospital of China
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, China
Site recruitment: Not reported
The First Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Not reported
Yanbian University Hospital
Yanbian, Jilin, China
Site recruitment: Not reported
The Sixth People's Hospital of Shenyang
Shenyang, Liaoning, China
Site recruitment: Not reported
Jinan Infectious Disease Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Qilu Hospital of Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
The Six People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Tangdu Hospital
Xi’an, Shanxi, China
Site recruitment: Not reported
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Site recruitment: Not reported
Xijing Hospital
Xi’an, Shanxi, China
Site recruitment: Not reported
West China Hospital Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
XiXi Hospital of Hangzhou
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Worldwide Study Finder

Find a study

Registry search results

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

Explore the world’s study registries

Worldwide

Africa

Americas

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Abscopal Effect for Metastatic Small Cell Lung Cancer

Optimized Treatment and Regression of HBV-induced Early Cirrhosis

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Dendritic Cell Based Therapy for Breast Cancer Patients

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

Dendritic Cell Based Therapy of Renal Cell Carcinoma

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Efficacy of Thymosin alpha1 for Severe Sepsis

Asia

Middle East

Europe

Oceania